Hypertriglyceridemia Therapeutics Market, By Type (Primary and Secondary), By Drug Class (Statins, Fibrates, Omega-3 Fatty Acids, HMG-CoA Reductase inhibitors, and Niacin), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) -

Published In : Jul 2023

Code : CMI4020

Pages :230

Formats :

Excel and PDF

Industry : Pharmaceutical

Hypertriglyceridemia Therapeutics MarketSize and Trends

Global hypertriglyceridemia therapeutics market is estimated to be valued at US$ 11.06 Billion in 2023 and is expected to exhibit a CAGR of 5.0% during the forecast period (2023-2030).

Figure 1. Global Hypertriglyceridemia Therapeutics Market Share (%), By Type, 2023

Figure 2. Global Hypertriglyceridemia Therapeutics Market Share (%), By Region, 2023

Global Hypertriglyceridemia Therapeutics Market– Drivers

Increase in sedentary lifestyle

Increasing sedentary lifestyle is expected to drive the growth of global hypertriglyceridemia therapeutics market over the forecast period. For instance, in January 2022, according to the Forbes, 25% of U.S. adults are physically inactive according to the study released by the Centers for Disease Control and Prevention (CDC), Puerto Rico adults in U.S had the highest level of inactivity at 49.4%, with Colorado the lowest at 17.7%.

Increasing product approval by the key players

Increasing product approval by the market key players is expected to drive the global hypertriglyceridemia therapeutics market over the forecast period. For instance, in April 2020, Dr. Reddy’s Laboratories Ltd., an India-based multinational pharmaceutical, launched Fenofibrate Tablets United States Pharmacopeia, a therapeutic equivalent generic version of Tricor (fenofibrate) Tablets, approved by the U.S. Food and Drug Administration (USFDA). Dr. Reddy’s Fenofibrate Tablets USP are available in 54 mg doses in bottle count sizes of 90 and 160 mg doses in bottle count sizes of 90 and 500.

Over the forecast period, the global hypertriglyceridemia therapeutics market is anticipated to rise due to the rising prevalence of cardiovascular diseases (CVD) such atherosclerosis, hypertension, and coronary heart disease and sedentary lifestyle. For instance, on March 16 2023, according to the World Health Organization (WHO), an estimated 1.28 billion adults aged 30–79 years worldwide have hypertension, most (two-thirds) living in low- and middle-income countries such as Afghanistan, Haiti, Ghana, etc. An estimated 46% of adults with hypertension are unaware that they have the condition and a less than half of adults (42%) with hypertension are diagnosed and treated.